Brief: Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential Of Avexitide In Patients With Post-Bariatric Hypoglycemia And Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries
13/06/2022 13:16
June 13 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS ANNOUNCES NEW DATA SUPPORTING
BROADER
POTENTIAL OF AVEXITIDE IN PATIENTS WITH POST-BARIATRIC
HYPOGLYCEMIA AND HYPERINSULINEMIC HYPOGLYCEMIA AFTER
GASTROINTESTINAL SURGERIES
* EIGER BIOPHARMACEUTICALS INC - AVEXITIDE SIGNIFICANTLY
REDUCED
NUMBER OF HYPOGLYCEMIA EVENTS AND AMOUNT OF TIME SPENT IN
HYPOGLYCEMIA
* EIGER BIOPHARMACEUTICALS INC - AVEXITIDE WAS
WELL-TOLERATED,
WITH NO SERIOUS ADVERSE EVENTS OR PARTICIPANT WITHDRAWALS
Source text for Eikon: ID:nPn4B8N8Ga
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview